Bird-derived gene tool inserts plant DNA 30 times more efficiently than CRISPR Phys.org 05:56 Tue, 23 Jun
Study Explains How Anti-CRISPR Protein Promotes The Spread Of Hospital-Acquired Infections Scoop 06:32 Fri, 19 Jun
More Than 100 Scientific Papers Leveraged the Dante Labs Technology for Research on Transcriptomics, CRISPR Gene Editing, Ancient DNA samples, Rare Diseases and Oncology Business Wire (Press Release) 18:24 Thu, 18 Jun
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year The Motley Fool 14:28 Thu, 18 Jun
Scribe Therapeutics Awarded More Than $25 Million From Cirm to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials Business Wire (Press Release) 13:06 Thu, 18 Jun
Translation-dependent degradation of cas12 mRNA triggered by an anti-CRISPR Nature.com 16:24 Wed, 17 Jun
From bench to biome: CRISPR phages could precision edit the microbiome NutraIngredients.com 16:06 Mon, 15 Jun
IntelliGenome Announces Strategic Partnership with Ctr Scientific to Advance CRISPR-TB in Mexico PR Newswire (Press Release) 13:35 Mon, 15 Jun
Phase 3 study of in vivo CRISPR therapy for hereditary angioedema successfully completed News-Medical.Net 03:55 Sun, 14 Jun
CRISPR Therapeutics (CRSP) Stock Valuation Check After Recent Pullback And Conflicting DCF And P/B Signals Simply Wall St 10:20 Sat, 13 Jun
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know Zacks 00:03 Thu, 11 Jun
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? The Motley Fool 18:28 Mon, 08 Jun
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential The Motley Fool 17:51 Wed, 03 Jun
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out The Motley Fool 08:21 Wed, 03 Jun
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking The Motley Fool 17:41 Mon, 01 Jun
Vertex sued in first UPC CRISPR dispute; ToolGen Cas9 patent ruled invalid by EPO Opposition Division IAM 13:31 Mon, 01 Jun
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? The Motley Fool 17:45 Sun, 31 May
Scientists develop safer CRISPR technique using gentler DNA nicking approach News-Medical.Net 02:47 Thu, 28 May
From bases to breakthroughs: Editing cancer’s weak spots with CRISPR Sanger Institute Blog 09:49 Tue, 26 May
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? The Motley Fool 01:46 Tue, 26 May
